Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Todos Medical Ltd. (TOMDF)
Tel Aviv, IL
Todos Medical Ltd. operates as an in vitro diagnostics company, concentrating on the creation and commercialization of blood tests for the early detection of cancer and Alzheimer's disease, primarily serving the United States market. The company's innovative approaches to cancer diagnostics include the Total Biochemical Infrared Analysis (TBIA), a proprietary screening technology that uses peripheral blood spectroscopy to investigate cancer's effects on the immune system. Another key offering is the Lymphocyte Proliferation Test (LPT), a diagnostic blood assay designed to assess how peripheral blood lymphocytes and monocytes react to exogenous mitogenic stimulation, which induces cell cycle entry. Their cancer product lineup includes TM-B1 and TM-B2 for breast cancer screening, alongside the TMC blood test for diagnosing colon cancer. Beyond oncology, Todos Medical is also actively developing blood-based tests for identifying neurodegenerative conditions, notably Alzheimer's disease. In addition to its diagnostic portfolio, the company markets Tollovid, a dietary supplement acting as a 3CL protease inhibitor, formulated to bolster a healthy immune response against common coronaviruses. Furthermore, Tollovir, an antiviral treatment for Covid-19, is currently progressing through Phase 2 clinical trials. Todos Medical Ltd. engages in strategic alliances, including a collaboration with Integrated Health LLC, and has various agreements in place for developing SARS-nCoV-2 screening tests and distributing specific COVID-19 test kits. The company was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +900.00% | +0.00% | +900.00% | +0.00% | -98.89% | -99.96% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Diagnostics & Research: +7.9%-37.1% Q4'22: -68.5% (vs Q4'21)
-
EPS growth Medical - Diagnostics & Research: +30.8%+72.5% ★ Q4'22: +86.3% (vs Q4'21)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-254.3% Q4'22: +63.0% (vs Q4'21)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-131.8% Q4'22: -146.0% (vs Q4'21)
-
ROIC Medical - Diagnostics & Research: +5.2%-296.3% Q4'22: -239.3% (vs Q4'21)
-
Share dilution Medical - Diagnostics & Research: 0.0%+109.8% Q4'22: +93.5% (vs Q4'21)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-4.08× Q4'22: -5.09× (vs Q4'21)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Investment Holdings, LLC (ID 82-1548155) | 151.40M | 9.01% | 151.40M | — | 151.40M | — | CO | USA | 2023-02-17 | ↗ |
| 2 | Rill | 151.40M | 9.01% | 151.40M | — | 151.40M | — | IN | USA | 2023-02-17 | ↗ |
| 3 | Resources, LLC | 76.96M | 6.70% | 76.96M | — | 76.96M | — | PN | United States of America | 2022-04-06 | ↗ |
| 4 | Advisors LLC | 67.42M | 8.50% | — | 67.42M | — | 67.42M | PN | Delaware | 2021-09-15 | ↗ |
| 5 | Fund I, LP | 67.42M | 8.50% | — | 67.42M | — | 67.42M | PN | Delaware | 2021-09-15 | ↗ |
| 6 | Geller | 67.42M | 8.50% | — | 67.42M | — | 67.42M | IN | Delaware | 2021-09-15 | ↗ |
| 7 | Strategic Investment Holdings, LLC (ID 82-1548155) | 48.71M | 22.10% | 18.61M | — | 18.61M | — | CO | USA | 2020-07-15 | ↗ |
| 8 | S | 44.48M | 4.86% | 44.48M | — | 44.48M | — | CO | USA | 2021-11-01 | ↗ |
| 9 | HEALTHCARE 365 TECH LLC (ID – 86-1741291) | 24.00M | 5.76% | 24.00M | — | 24.00M | — | CO | United States of America | 2021-02-05 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-28 | COMMISSIONG GERALD | Director / Officer | P-Purchase | A | Ordinary Shares | 5,000,000 | 0.00 | 4.5K | 7,055,680 | — | ↗ |
| 2022-08-24 | COMMISSIONG GERALD | Director / Officer | P-Purchase | A | Ordinary Shares | 1,000,000 | 0.03 | 32.0K | 2,051,480 | — | ↗ |
| 2021-06-30 | COMMISSIONG GERALD | Director / Officer | P-Purchase | A | Ordinary Shares | 1,051,480 | 0.03 | 35.8K | 1,051,480 | — | ↗ |
| 2021-04-05 | Strategic Investment Holdings, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 45,036,321 | — | ↗ |
| 2021-04-01 | Strategic Investment Holdings, LLC | 10% Owner | S-Sale | D | Common Stock | 98,300 | 0.06 | 5.5K | 47,909,885 | — | ↗ |
| 2021-03-31 | Strategic Investment Holdings, LLC | 10% Owner | S-Sale | D | Common Stock | 100,000 | 0.05 | 5.3K | 48,358,185 | — | ↗ |
| 2020-07-07 | Strategic Investment Holdings, LLC | 10% Owner | P-Purchase | A | Common Stock | 18,608,113 | 0.08 | 1.43M | 48,708,185 | — | ↗ |
| 2020-04-01 | Strategic Investment Holdings, LLC | 10% Owner | P-Purchase | A | Common Stock | 13,008,976 | 0.08 | 1.00M | 30,100,072 | — | ↗ |
| 2020-01-21 | Strategic Investment Holdings, LLC | 10% Owner | P-Purchase | A | Common Stock | 17,091,096 | 0.06 | 1.01M | 17,091,096 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gerald E. Commissiong | Chief Executive Officer, President & Director | 465.3K | male |
| Daniel Hirsch | Chief Financial Officer & Director | 315.3K | male |
| Jorge A. Leon | Chief Science Officer | — | — |
| Joseph Wee | Managing Director of Singapore | — | — |
| Paula T. Trzepacz | Chief Medical Officer of Neurology | — | — |
| Ilanit Halperin | Corporate Controller | — | female |
| Chris Gross | Vice President of Operations | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TOMDF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
